Cardiology

An analysis of nearly 1000 patients from Spain is providing clinicians with insight into factors that could help predict negative outcomes among patients with stable coronary artery disease.

Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes.

Investigators noted that several types of AID systems improved Time-in-Range and HbA1c with minimal concerns around severe hypoglycemia in type 1 diabetes care.

The treatment was effective across all weight groups.

The latest data from the digital care transformation program provides insight into effects of digital monitoring programs on helping patients achieve blood pressure and cholesterol goals.

More than 90% of patients in hypertension and lipid management accomplished their predetermined goals after completing the remote program.

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.

After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.

Bentracimab achieved the predetermined primary endpoint of immediate and sustained reversal of the antiplatelet effects of ticagrelor in the REVERSE-IT trial.

Young smokers in 2017 were more likely to have other comorbid conditions including hypertension, diabetes, and obesity.

A new study from the American Heart Association Scientific Sessions 2021 found that atherosclerotic cardiovascular disease risk increases with sdLDL-C levels, regardless of sex or race.

The ASCEND trial indicates low-dose aspirin use was associated with a nonsignificant reduction in risk of dementia among patients with diabetes and no history of cardiovascular disease.

Data from the ASCEND trial provide clinicians with insight into the risk of dementia based on long-term use of low-dose aspirin among patients with diabetes and no history of cardiovascular disease.

There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.

A study from the Intermountain Heart Institute details the risk of pericarditis and myocarditis associated with COVID-19 vaccines among patients from within their institution's health system.

Data from the Fitbit Heart study presented at AHA 2021 suggest a novel algorithm for detecting irregular heart rhythms had a positive predictive value of 98% for detecting atrial fibrillation in patients with undiagnosed atrial fibrillation.

Data from the CRAVE trial, which was presented at AHA 2021, suggests consumption of coffee could impact heart rhythm, daily sleep, and physical activity.

Results from the 6-month analysis of the RAPID CABG trial indicate stopping ticagrelor use 2-3 days prior to CABG was not associated with an increased risk in bleeding compared to discontinuing use 5-7 days prior to surgery.

Results of the AVATAR trial suggest early surgery could reduce the risk of MACE and mortality compared to a conservative treatment approach among patients with severe asymptomatic aortic stenosis and a normal LVEF.

Deepak Bhatt, MD, MPH, provides perspective on the results of the REDUCE-IT PAD analysis he presented at the American Heart Association 2021 Scientific Sessions.

Laura Ross, PA-C, details her experience at the American College of Lifestyle Medicine 2021 meeting and the role of lifestyle modification in preventive medicine.

Manesh Patel, MD, program committee chair of the AHA 2021 Scientific Sessions, discusses this year's conference, previews the late-breaking sessions, and reflects on his experience as chair.

Epinephrine before defibrillation was associated with lower odds of survival to discharge, favorable neurological survival, and survival after acute resuscitation

Data presented at ASN Kidney Week 2021 suggests dapagliflozin use was associated with a reduction in the rate of kidney function decline in patients with chronic kidney disease, regardless of whether they have diabetes.